Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research · 2008 · 2K citations · Full text

Medicine, Oncology, Pharmacology +16

Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML

Catriona Jamieson, Laurie Ailles, Scott J. Dylla et al. · New England Journal of Medicine · 2004 · 1.5K citations · Full text

Life Sciences, Cell Biology, Hematology +17

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized

Mark F. van Delft, Andrew H. Wei, Kylie D. Mason et al. · Cancer Cell · 2006 · 1.2K citations · Full text

Life Sciences, Cell Biology, Pharmacology +10

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

Morris E. Feldman, Beth Apsel, Aino Uotila et al. · PLoS Biology · 2009 · 1.1K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia

Marina Konopleva, Rooha Contractor, Twee Tsao et al. · Cancer Cell · 2006 · 1K citations · Full text

Life Sciences, Oncology, Pharmacology +16